Evaluation of the Invest in Play Program - a New Parent Intervention for Children With Problem Behavior
Launched by UNIVERSITY OF TROMSO · May 19, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program called "Invest in Play" (iiP) designed to help parents of children aged 6 to 12 who are experiencing problem behaviors, such as being disruptive or having trouble paying attention. The goal of the program is to see if it can reduce these challenging behaviors in children and improve parenting skills. Families will be randomly divided into two groups: one will participate in the iiP program, and the other will not. Researchers will gather information from both groups through surveys before and after the program to see if the iiP helps.
To be eligible for this trial, parents need to have children who are referred for treatment of behavioral problems and whose behaviors are considered more challenging than most children, based on a specific screening tool. However, children with severe developmental delays, autism spectrum disorder, or those who cannot understand Norwegian are not eligible to participate. This program is not currently recruiting participants, but it aims to provide valuable insights into how parents can better support their children’s behavior.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parents of children between 6-12 years of age referred to out-patient clinics for treatment of behavioural problems.
- • Children scoring above a pre-defined mean cut off score (over the 90 percentile) on the Eyberg Child Behavior Inventory (ECBI; Eyberg \& Ross, 1978) based on Norwegian norms (Reedtz et al., 2008), as reported by parents.
- Exclusion Criteria:
- • - Severe developmental delay (in children or parents), autism spectrum disorder, inability to understand Norwegian, or other reasons why the parent(s) are not expected to benefit from group therapy.
About University Of Tromso
The University of Tromsø, located in Norway, is an esteemed academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a clinical trial sponsor, the university leverages its cutting-edge facilities and interdisciplinary expertise to advance medical research, enhance patient care, and contribute to scientific knowledge. With a strong emphasis on ethical standards and regulatory compliance, the University of Tromsø collaborates with healthcare professionals and researchers to design and implement clinical trials that address critical health challenges, ultimately aiming to improve health outcomes and inform clinical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Patients applied
Trial Officials
Lene-Mari P. Rasmussen, Ph.d
Principal Investigator
UiT The Arctic University of Norway
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported